



(12) Translation of
european patent specification

(11) NO/EP 2176208 B1

NORWAY

(19) NO
(51) Int Cl.
C07C 47/277 (2006.01)
A61K 31/215 (2006.01)
A61K 31/265 (2006.01)
A61K 31/27 (2006.01)
A61P 1/08 (2006.01)
A61P 25/04 (2006.01)
A61P 29/00 (2006.01)
C07C 39/23 (2006.01)
C07C 69/017 (2006.01)
C07C 69/12 (2006.01)
C07C 69/675 (2006.01)
C07C 69/68 (2006.01)
C07C 69/708 (2006.01)
C07C 69/96 (2006.01)
C07C 219/04 (2006.01)
C07C 229/12 (2006.01)
C07C 271/44 (2006.01)
C07C 271/52 (2006.01)

Norwegian Industrial Property Office

(21) Translation Published 2015.06.22

(80) Date of The European Patent Office Publication of the Granted Patent 2015.01.21

(86) European Application Nr. 08796904.4

(86) European Filing Date 2008.07.30

(87) The European Application's Publication Date 2010.04.21

(30) Priority 2007.07.30, US, 952746 P

(84) Designated Contracting States: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(73) Proprietor Zynerba Pharmaceuticals, Inc., 170 North Radnor Chester Road, Suite 350, Radnor, PA 19087, US-USA

(72) Inventor STINCHCOMB, Audra, Lynn, 1122 Oak Hill Drive, Lexington, KY 40505, US-USA
GOLINSKI, Miroslaw, Jerzy, 3877 Aria Lane, Lexington, KY40514, US-USA
HOWARD, Jeffery, Lynn, 114 Annette Drive, Richmond, KY 40475, US-USA
HAMMELL, Dana, Carmel, 150 Placid Drive, Georgetown, KY 40324, US-USA
BANKS, Stan, Lee, 101 East Darbywood Drive, Frankfort, KY 40601, US-USA

(74) Agent or Attorney Hynell AS, Parkveien 53 B, 0256 OSLO, Norge

(54) Title **Prodruger av cannabidiol, sammensetninger som omfatter prodruger av cannabidiol og fremgangsmåter for anvendelse av disse**

(56) References Cited:
WO-A-99/53917
WO-A-2004/039317
WO-A-2004/082620
WO-A-2006/133941
WO-A-2008/107879

US-A1- 2002 111 377

ABU-LAFI ET AL.: "Role of hydroxyl groups in chiral recognition of cannabinoids by carbamated amylose" JOURNAL OF CHROMATOGRAPHY, vol. 679, 1994, pages 47-58, XP002505687
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US;
WEINER, BEN Z. ET AL: "Monomers and polymers of .DELTA.1(6)-tetrahydrocannabinol and cannabidiol" XP002505688 retrieved from STN Database accession no. 84:59754 &
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , 10(1), 79-83 CODEN: EJMCA5; ISSN: 0223-5234, 1975,

DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US;
HANDRICK, G. RICHARD ET AL: "Hashish. 20. Synthesis of (.+-.)-.DELTA.1- and .DELTA.6-3,4-cis-cannabidiols and their isomerization by acid catalysis" XP002505689 retrieved from STN Database accession no. 87:68497 & JOURNAL OF ORGANIC CHEMISTRY , 42(15), 2563-8 CODEN: JOCEAH; ISSN: 0022-3263, 1977,

DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KNAUS, E. E. ET AL: "The separation, identification, and quantitation of cannabinoids and their t-butyltrimethylsilyl, trimethylsilylacetate, and diethylphosphate derivatives using high-pressure liquid chromatography, gas-liquid chromatography, and mass spectrometry" XP002505690 retrieved from STN Database accession no. 86:38182 & JOURNAL OF CHROMATOGRAPHIC SCIENCE , 14(11), 525-30 CODEN: JCHSBZ; ISSN: 0021-9665, 1976,

DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US;
MECHOULAM, R. ET AL: "Hashish. IV. Isolation and structure of cannabinolic, cannabidiolic, and cannabigerolic acids" XP002505691 retrieved from STN Database accession no. 63:16677 & TETRAHEDRON , 21(5), 1223-9 CODEN: TETRAB; ISSN: 0040-4020, 1965,

DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US;
PETRZILKA, T. ET AL: "Synthesis of hashish components. IV" XP002505692 retrieved from STN Database accession no. 71:21989 & HELVETICA CHIMICA ACTA , 52(4), 1102-34 CODEN: HCACAV; ISSN: 0018-019X, 1969,

DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US;
MADINAVEITIA, A. ET AL: "Cannabis indica. XI. An examination of the alkali-soluble portion of American-hemp resin" XP002505693 retrieved from STN Database accession no. 37:3626 & JOURNAL OF THE CHEMICAL SOCIETY 628-30 CODEN: JCSEA9; ISSN: 0368-1769, 1942,

DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US;
HATTORI, HIDEKI ET AL: "Gas chromatography/negative ion chemical ionization mass spectrometry of cannabinoids in human samples" XP002505694 retrieved from STN Database accession no. 100:97716 & IYO MASU KENKYUKAI KOENSHU , 8, 159-60 CODEN: KIMKDN; ISSN: 0910-870X, 1983,







PILLAI OMATHANU ET AL: "Physicochemical Evaluation, in Vitro Human Skin Diffusion, and Concurrent Biotransformation of 3-O-Alkyl Carbonate Prodrugs of Naltrexone"
PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 21, no. 7, 1 January 2004 (2004-01-01), pages 1146-1152, XP002469233 ISSN: 0724-8741

STINCHCOMB A L ET AL: "PERMEATION OF BUPRENORPHINE AND ITS 3-ALKYL-ESTER PRODRUGS THROUGH HUMAN SKIN" PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 13, no. 10, 1 October 1996 (1996-10-01), pages 1519-1523, XP008016388 ISSN: 0724-8741







Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>



Patentkrav

1. Forbindelse valgt fra gruppen som består av:



5





- 5 **2.** Farmasøytisk sammensetning som omfatter:
- (a) en forbindelse som beskrevet i krav 1; og
- (b) en farmasøytisk akseptabel eksipiens.
- 10 **3.** Anvendelse av en forbindelse som beskrevet i krav 1 for fremstillingen av et
- medikament for behandlingen av en medisinsk tilstand i et pattedyr, hvori den
- medisinske tilstanden er valgt fra gruppen som består av: kvalme, oppkast, emesis,
- smerte, avmagringssyndrom, HIV-avmagring, kjemoterapiindusert kvalme og oppkast,
- alkoholbrukslidelser, dystoni, multippel sklerose, inflammatoriske tarmlidelser, artritt,
- dermatitt, revmatoid artritt, systemisk lupus erythematosus, anti-inflammatoriske, anti-
- 15 konvulsante, anti-psykotiske, anti-oksiderende, nevrobeskyttende, anti-kreft,
- immunomodulatoriske virkninger, perifer nevropatisk smerte, nevropatisk smerte
- assosiert med post-herpetisk nevralgi, diabetisk nevropati, helvetesild, forbrenninger,
- aktinisk keratose, sår og ulcus i munnhulen, post-episiotomi smerte, psoriasis, pruritt,
- kontakt dermatitt, eksem, bulløs dermatitis herpetiformis, eksfoliativ dermatitt, mycosis
- 20 fungoides, pemfigus, alvorlig erythema multiforme (f.eks. Stevens-Johnson syndrom),
- seбореisk dermatitt, ankyloserende spondylitt, psoriatisk artritt, Reiters syndrom, gikt,
- kondrokalcinose, leddsmerte sekundært til dysmenoré, fibromyalgi,

muskelskjelleitmserte, nevropatisk-postoperative komplikasjoner, polymyositt, akutt ikke-spesifikk tenosynovitt, bursitt, epikondylitt, post-traumatisk osteoartritt, synovitt, juvenil revmatoid artritt og inhibering av hårvekst.

5 **4.** Anvendelse av en forbindelse ifølge krav 3 hvori nevnte forbindelse blir administrert enten transdermalt eller topisk.

5. Anvendelse av en forbindelse ifølge krav 1 for fremstillingen av et medikament som omfatter trinnene med å:

10 (a) kombinere en forbindelse ifølge krav 1 med en farmasøytisk eksipiens for å danne en farmasøytisk sammensetning;


(b) skape en doseringsform egnet for administrasjon til et pattedyr fra den farmasøytiske sammensetningen; og

(c) administrere doseringsformen til et pattedyr.


15

6. Anvendelse ifølge krav 5 hvori forbindelsen blir administrert ved en rute valgt fra gruppen som består av: transdermalt, topisk, oralt, bukkalt, sublingvalt, intravenøst, intramuskulært, vaginalt, rektalt, okulært, nasalt og follikulært.

20 **7.** Forbindelse ifølge krav 1, som er




8. Forbindelse ifølge krav 1, som er




25

9. Forbindelse ifølge krav 1, som er




10. Forbindelse ifølge krav 1, som er




5


11. Forbindelse ifølge krav 1, som er



10 12. Forbindelse ifølge krav 1, som er




13. Forbindelse ifølge krav 1, som er




15

14. Forbindelse ifølge krav 1, som er




15. Forbindelse ifølge krav 1, som er




5


16. Forbindelse ifølge krav 1, som er



10 17. Forbindelse ifølge krav 1, som er




18. Forbindelse ifølge krav 1, som er




15

19. Forbindelse ifølge krav 1, som er




20. Forbindelse ifølge krav 1, som er




5


21. Forbindelse ifølge krav 1, som er



10 22. Forbindelse ifølge krav 1, som er




23. Forbindelse ifølge krav 1, som er



15

24. Forbindelse ifølge krav 1, som er



25. Forbindelse ifølge krav 1, som er

